This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Are Investors Undervaluing McKesson (MCK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Attractive Medical Stocks to Buy After Earnings
by Shaun Pruitt
Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.
McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
Here's What Key Metrics Tell Us About McKesson (MCK) Q3 Earnings
by Zacks Equity Research
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CVS Health (CVS) Q4 Earnings Top Estimates, 2024 EPS View Down
by Zacks Equity Research
Robust sales growth across all three operating segments contributes to CVS Health's (CVS) Q4 revenues.
Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip
by Zacks Equity Research
Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.
GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve
by Zacks Equity Research
GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
5 Dividend Growth Stocks to Buy for a Safe Portfolio
by Sweta Killa
Installed Building Products (IBP), PACCAR. (PCAR), McKesson (MCK), Republic Services (RSG) and PulteGroup (PHM) seem solid choices for a safe portfolio amid the current market volatility.
IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.
McKesson Corporation (MCK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's How Much You'd Have If You Invested $1000 in McKesson a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and McKesson (MCK) have performed compared to their sector so far this year.
Exploring Analyst Estimates for McKesson (MCK) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of McKesson (MCK) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.